Tetraphase Pharmaceuticals
Investor Relations Department
480 Arsenal Street, Suite 110
Watertown, MA 02472
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: TTPH	
Last Trade:	8.11
Trade Time:	4:00 PM ET Mar 24, 2017
Change:	0.03 (+0.371%)
Day Range	8.01 - 8.27
52-Week Range	3.11 - 8.69
Volume	497,228

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

… (more)

Stock Information



Press Releases [View all]

Mar 8, 2017
Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones

Mar 6, 2017
Tetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference

Mar 3, 2017
Tetraphase Pharmaceuticals to Host Conference Call on March 8 to Discuss Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update

Jan 17, 2017
Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI

Dec 19, 2016
Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline

Financials & Filings [View all]

Mar 13, 2017
Annual Report (10-K)

Apr 29, 2016
Proxy Statement (DEF 14A)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)

May 4, 2016
Quarterly Report (10-Q)